Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice.
Gastrin-releasing peptide (GRP) has been implicated in the itch-scratch cycle. We investigated if this gut-brain-skin peptide plays a role in the compulsive, hindleg scratching of the neck of mice by 5'-guanidinonaltrindole (GNTI), the kappa opioid receptor antagonist, and in the antipruritic activity of nalfurafine, the kappa opioid agonist. Previously, we showed that GNTI (0.03-1mg/kg, s.c.) elicits dose-related scratching and that nalfurafine (0.001-0.02mg/kg, s.c.) inhibits this behavior in mice. Utilizing immunohistochemistry, GRP positive nerve fibers were detected in mouse skin and superficial layer of the dorsal horn of the spinal cord as well as GRP positive cells in the dorsal root ganglion. Pretreating mice with either a pseudopeptide GRP receptor antagonist, RC-3095 (10-30mg/kg, s.c. at -15min), or a peptide GRP receptor antagonist, [d-Phe(6)]bombesin(6-13) methyl ester (2-100nmol, i.t. at -10min), did not suppress GNTI-induced scratching. However, pretreating mice with either antagonist inhibited scratching precipitated by the GRP receptor agonist, GRP(18-27) (2nmol, i.t.). Pretreating mice with a muscarinic M(1) receptor agonist, McN-A-343 (1.5-15μg/5μl, i.t. at -10min) antagonized GNTI-induced scratching. Norbinaltorphimine (20mg/kg, i.p. at -18 to -20h), a kappa opioid antagonist, countered the antiscratch activity of nalfurafine. We conclude that (a) the GRP receptor system does not mediate GNTI-induced scratching and (b) the kappa opioid system is involved, at least in part, in the scratch suppressing activity of nalfurafine.
Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Saadet
S
Inan
Nae J
NJ
Dun
Alan
A
Cowan
D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride / Q000494:pharmacology; D000818:Animals; D001839:Bombesin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003192:Compulsive Behavior / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control; D005727:Ganglia, Spinal / Q000378:metabolism; D019886:Gastrin-Releasing Peptide / Q000378:metabolism*; D006120:Grooming / Q000187:drug effects; D006146:Guanidines; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051379:Mice; D009019:Morphinans / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009412:Nerve Fibers / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000494:pharmacology; D011537:Pruritus / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control; D043643:Receptor, Muscarinic M1 / Q000819:agonists / Q000037:antagonists & inhibitors; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors; D012867:Skin / Q000294:innervation / Q000378:metabolism; D013116:Spinal Cord / Q000378:metabolism; D013141:Spiro Compounds / Q000494:pharmacology
C411465:17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan; D006146:Guanidines; D009019:Morphinans; D010446:Peptide Fragments; D043643:Receptor, Muscarinic M1; D018004:Receptors, Bombesin; D017473:Receptors, Opioid, kappa; D013141:Spiro Compounds; C046338:telenzepine; C071101:bombesin (6-13), Phe(6) methyl ester-; C071363:bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-; C111212:TRK 820; D010890:Pirenzepine; D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; D009271:Naltrexone; D019886:Gastrin-Releasing Peptide; C040794:neuromedin C; D001839:Bombesin